Central Laboratory Core

项目总结-中心实验室核心 中心实验室（CL）评估病毒和免疫合作伙伴关系核心的总体目标 艾滋病病毒感染者肿瘤学景观交叉点（PAVILION）将提供集中的 对注释良好的生物标本进行生物库、病毒学和免疫学评估，以支持 建议的转化研究以及未来的PAVILION试点项目。CL核心将由三个人共同领导 杰出的研究人员Johann Schneider博士（南非）、Zvavahera（Mike）Chirenje博士（津巴布韦）和 Tim Waterboer（德国），他们具有互补的专门知识。CL联合领导人设计了一个强大的， 灵活的管道和一系列基于基础设施和长期的分析方法 PAVILION与南非，津巴布韦， 美国和德国。CL Core有目的地将这种独特的专业知识与 低收入和中等收入国家（LMIC）伙伴国家有效地推进与肿瘤相关的知识， 患者特征。这些知识可以为有效预防和癌症的发展提供信息 治疗干预措施，以减少中低收入国家艾滋病毒感染者的癌症负担 受艾滋病毒的严重影响。为了实现总体目标，CL核心将提供集中的， 研究质量病理学评价，用于采集组织的终点判定、DNA和RNA提取， HPV和EBV检测和基因分型，RNA表达分析，多重病毒血清学评估，以及 肿瘤微环境的免疫学评估，用于拟议和未来的项目。这些活动 组织成以下目标： 目标1：作为南非和津巴布韦的集中生物库资源， 处理和储存生物样本以支持PAVILION研究 LMIC环境中高负担和研究不足的病毒性癌症，包括非宫颈HPV相关的 癌症（肛门，口咽，阴茎和外阴）和结膜癌，怀疑但截至目前 艾滋病毒感染者中病毒病因不明。 目标2：提供生物标本的集中病毒学和免疫学检测，以支持拟议的 和未来的PAVILION研究这一目标提供了集中的病毒和免疫学检测库标本 通过一套强有力的分析方法，支持拟议的和未来的研究目标， PAVILION合作机构，包括LMIC和非LMIC站点。 目的3：提供集中的专家病理学，以支持拟议和未来的PAVILION研究。 aim为库存组织标本提供全面和专家集中的病理学裁定， 支持拟议的转化研究和未来的发展核心试点研究。

PROJECT SUMMARY – CENTRAL LABORATORY CORE The overarching goal of the Central Laboratory (CL) Core for the Partnership to Assess Viral and Immune Landscape Intersections with Oncology for People Living with HIV (PAVILION) is to provide centralized biobanking and virologic and immunologic assessment of well annotated biospecimens in support of the proposed translational studies as well as future PAVILION pilot projects. The CL Core will be co-led by three exceptional investigators, Drs. Johann Schneider (South Africa), Zvavahera (Mike) Chirenje (Zimbabwe), and Tim Waterboer (Germany), who have complementary expertise. The CL Co-Leaders have designed a robust yet flexible pipeline and range of analytical methodologies that builds upon the infrastructure and long-term international collaborations established by the PAVILION partnering investigators in South Africa, Zimbabwe, the US, and Germany. The CL Core purposefully pairs this unique expertise with established laboratories in the low- and middle-income country (LMIC) partner countries to efficiently advance knowledge related to tumor and patient characteristics. This knowledge can then inform the development of effective prevention and cancer treatment interventions to reduce the burden of cancer for people living with HIV (PLWH) in LMICs disproportionately impacted by HIV. To achieve the overarching goal, the CL Core will provide centralized, research-quality pathology evaluation for endpoint adjudication of collected tissues, DNA and RNA extraction, HPV and EBV detection and genotyping, RNA expression analysis, multiplex viral serology assessment, and immunological evaluation of the tumor microenvironment for the proposed and future projects. These activities are organized into the following Aims: Aim 1: Serve as a centralized biobanking resource in South Africa and Zimbabwe for the collection, processing, and storage of biospecimens in support of PAVILION studies This aim provides biobanking of high-burden and under-researched viral cancers in LMIC settings, including non-cervical HPV-associated cancers (anal, oropharyngeal, penile, and vulvar) and conjunctival cancer, with a suspected but as of yet unidentified viral etiology amongst PLWH. Aim 2: Provide centralized virologic and immunologic testing of biospecimens in support of proposed and future PAVILION studies This aim provides centralized viral and immunologic testing of banked specimens in support of proposed and future study aims through a robust set of analytical methodologies across four PAVILION partnering institutions, including LMIC and non-LMIC sites. Aim 3: Provide centralized expert pathology in support of proposed and future PAVILION studies This aim provides comprehensive and expert centralized pathology adjudication of banked tissue specimens in support of the proposed translational studies and future Developmental Core pilot studies.